Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $978.0 million.

  • Kymera Therapeutics' Liabilities and Shareholders Equity rose 6.49% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 billion, marking a year-over-year increase of 24.95%. This contributed to the annual value of $978.0 million for FY2024, which is 69.87% up from last year.
  • Kymera Therapeutics' Liabilities and Shareholders Equity amounted to $978.0 million in FY2024, which was up 69.87% from $575.8 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $978.0 million for FY2024, and its period low was $487.2 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $719.0 million, with a median of $603.1 million in 2022.
  • In the last 5 years, Kymera Therapeutics' Liabilities and Shareholders Equity skyrocketed by 317.45% in 2020 and then declined by 4.54% in 2023.
  • Yearly analysis of 5 years shows Kymera Therapeutics' Liabilities and Shareholders Equity stood at $487.2 million in 2020, then increased by 24.37% to $605.9 million in 2021, then declined by 0.46% to $603.1 million in 2022, then fell by 4.54% to $575.8 million in 2023, then soared by 69.87% to $978.0 million in 2024.